CGT

Rogers $1M Season of Canada’s Got Talent: Top Performances from Tonight’s Episode on Citytv

Retrieved on: 
Wednesday, April 3, 2024
QC, CIBC, Head, BALL, HEAD, Toronto Maple Leafs, Magic, Glass, Wine, CGT, Lilly, AIR, TROY, Singing, MICHAEL

DANIEL POWTER (Vernon, BC) surprised the audience by singing “Bad Day,” an original song he wrote that topped the charts for several weeks in 2005.

Key Points: 
  • DANIEL POWTER (Vernon, BC) surprised the audience by singing “Bad Day,” an original song he wrote that topped the charts for several weeks in 2005.
  • MITCHELL HRYCAN (Saskatoon, SK) duped the judges when his twin, MICHAEL HRYCAN, surprised the crowd in a shocking twist!
  • Together with Canada’s Got Talent, Rogers is committed to investing in premium original Canadian content while fostering homegrown talent.
  • Last year, Rogers contributed approximately $950M to Canadian content and produced over 12,700 hours of unique Canadian programming.

Rogers $1M Season of Canada’s Got Talent: Top Performances from Tonight’s Episode on Citytv

Retrieved on: 
Wednesday, March 20, 2024
CIBC, MAT, AB, Carbonear, Talent (measurement), Kardinal Offishall, MYM, CGT, Lilly, Queen, Film industry

– Rogers is giving this year’s winner $1M, the largest cash prize in Canadian television history –

Key Points: 
  • – Rogers is giving this year’s winner $1M, the largest cash prize in Canadian television history –
    – Catch up on tonight’s episode of Canada’s Got Talent on-demand or stream on Citytv+.
  • Singer MATTHEW COOPER’s (Carbonear, NL) performance of “Who Wants To Live Forever” by Queen, brought all four judges to their feet.
  • 4-year-old YUVIN MARASINI (Ajax, ON) – the youngest contestant to grace the CGT stage – performed an adorable cover of “Vacation” by Dirty Heads.
  • Together with Canada’s Got Talent, Rogers is committed to investing in premium original Canadian content while fostering homegrown talent.

Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference

Retrieved on: 
Monday, March 18, 2024
Patient, Role, GMP, CGT, Pharmaceutical industry

GERMANTOWN, Md., March 18, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralizing cell and gene therapies (CGTs), today announced that its CEO, Vered Caplan, will be presenting at the upcoming Bioprocessing Summit Europe.

Key Points: 
  • GERMANTOWN, Md., March 18, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralizing cell and gene therapies (CGTs), today announced that its CEO, Vered Caplan, will be presenting at the upcoming Bioprocessing Summit Europe.
  • Ms. Caplan is scheduled to present on Tuesday, March 19th, at 2:10 PM CET.
  • Bioprocessing Summit Europe brings together 750+ upstream, downstream, bioproduction, analytical and formulation professionals.
  • This 3-day, 12-track meeting has quickly become a premier meeting in the European bioprocessing calendar and is regarded by many as “the fastest growing bioprocessing meeting in Europe” following record growth in 2023.

INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy

Retrieved on: 
Wednesday, March 13, 2024
ICST, ISCT, International Society, Disease, Science, Career Achievement Award, Patient, Knowledge, Lead, Gene, University College London, GMP, CGT, CSO, Vaccine

Boca Raton, Florida, March 13, 2024 (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ: INMB) (the “Company”),  a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announces its Chief Scientific Officer and Co-Founder Mark Lowdell, Ph.D. has been awarded the Career Achievement Award in Cell and Gene Therapy by the International Society of Cell & Gene Therapy (ISCT), which the organization considers its highest honor. The award was announced as part of the annual ICST Major Awards announcement. Dr. Lowdell will receive the award during the organization’s annual meeting in Vancouver on May 29, 2024.

Key Points: 
  • The award was announced as part of the annual ICST Major Awards announcement.
  • Dr. Lowdell will receive the award during the organization’s annual meeting in Vancouver on May 29, 2024.
  • The ISCT is the elite organization in the field of cell and gene therapy,” said R.J. Tesi, M.D., INmune Bio’s Chief Executive Officer.
  • “I am honored to receive this most prestigious award in recognition of my life’s work and wish to thank the members of the ISCT.

Global Cell Counting Market to Hit $15.72 Billion by 2029, Fueled by Advancements in Cell Biology and Therapy - ResearchAndMarkets.com

Retrieved on: 
Friday, March 29, 2024
Research, Technology, University, Genetics, Artificial Intelligence, Education, Science, Nanotechnology, Biotechnology, Stem Cells, Other Technology, Health, Other Science, Automation, Quality control, Interdisciplinarity, Acute lymphoblastic leukemia, Growth, Prevalence, Application, Novartis, Patient, Conditional sentence, Cell biology, Lung, Concha bullosa, Hospital, Artificial intelligence, National Cancer Institute, AI, Regenerative medicine, Duchenne muscular dystrophy, Therapy, DEB, Miniaturization, Sarepta Therapeutics, CGT, FDA, DMD, Tisagenlecleucel, PDUFA, Pharmaceutical industry

The global cell counting market was valued at US$9.98 billion in 2023 and is expected to reach US$15.72 billion by 2029.

Key Points: 
  • The global cell counting market was valued at US$9.98 billion in 2023 and is expected to reach US$15.72 billion by 2029.
  • Advancements in cell biology, biotechnology, and medical research are driving demand for precise cell counting, especially with the rise of personalized medicine and regenerative therapies.
  • PDUFA dates for therapies could translate into an order book boost for the cell counting players in the market, resulting in market growth.
  • The global cell counting market is consolidated, with top five players holding approximately 70% share of the market.

AscellaHealth Releases Q1 2024 Specialty & Rare Pipeline Digest™: Captures Data and Progress of Groundbreaking Therapies in 2024

Retrieved on: 
Thursday, March 28, 2024
Other Health, Research, Pharmaceutical, Oncology, Hospitals, Genetics, Clinical Trials, Science, Biotechnology, FDA, Other Science, Health, Food and Drug Administration, Specialty, Patient, Multimedia, Food, Core Services, Doctor of Pharmacy, CGT, Fine chemical

AscellaHealth , a global healthcare and specialty pharmacy solutions organization, today released its latest Specialty & Rare Pipeline Digest™, the industry’s most comprehensive quarterly resource of new, pending and upcoming Specialty and Rare Disease drug launches, cell and gene therapies (CGT), biosimilars and generics.

Key Points: 
  • AscellaHealth , a global healthcare and specialty pharmacy solutions organization, today released its latest Specialty & Rare Pipeline Digest™, the industry’s most comprehensive quarterly resource of new, pending and upcoming Specialty and Rare Disease drug launches, cell and gene therapies (CGT), biosimilars and generics.
  • Continuing its tradition of providing a quarterly, complimentary, digital source of industry information to support the specialty drug market needs of all stakeholders and decision-makers, AscellaHealth captures essential information and updates on products that may impact treatment for millions of individuals worldwide who are affected by complex, chronic conditions or rare diseases.
  • This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20240328442451/en/
    “This comprehensive, timely report provides valuable insights and current data, reflecting the multitude of specialty products poised for introduction during the first quarter of 2024,” says Andy Szczotka, PharmD, chief pharmacy officer, AscellaHealth.

Charles River and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration

Retrieved on: 
Thursday, March 14, 2024
Research, Medical Devices, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Erythromelalgia, AAV, Diabetic neuropathy, CDMO, Patient, CRL, Good manufacturing practice, Gene, DNA, CAP, Chronic pain, Doctor of Philosophy, GMP, Navega, Therapy, Peripheral neuropathy, CGT, Pharmaceutical industry

Charles River Laboratories International, Inc. (NYSE: CRL) and Navega Therapeutics , Inc., a biotechnology company developing epigenetic gene therapies, today announced an AAV9 production program agreement.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) and Navega Therapeutics , Inc., a biotechnology company developing epigenetic gene therapies, today announced an AAV9 production program agreement.
  • As part of Charles River’s Cell and Gene Therapy (CGT) Accelerator Program (CAP), Navega will have access to established contract development and manufacturing (CDMO) capabilities and advisory services to produce an adeno-associated virus (AAV)-based gene therapy, NT-Z001, for Phase I clinical trials.
  • To bring NT-Z001 to clinic, Navega will leverage Charles River’s off-the-shelf plasmid products, custom plasmid capabilities, and Good Manufacturing Practice (GMP)-grade AAV production.
  • Join Ana Moreno, CEO, Navega Therapeutics on March 19 in San Francisco – see the full agenda and save your seat: https://bit.ly/3SW3VOV
    “The collaboration with Navega will tap into our premier gene therapy CDMO capabilities and robust AAV offerings.

Advancing CAR T-Cell Therapies with Clinical Trial Customization, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, March 25, 2024
ChromeOS, Genomics, Gene, Flow cytometry, Biomarker, Doctor of Philosophy, Clinical trial, Cytokine, CGT, Patient safety, Therapy, Cell, Pharmaceutical industry

TORONTO, March 25, 2024 /PRNewswire-PRWeb/ -- Bringing together best practices in genomics, flow cytometry, biomarkers and clinical trial operations.

Key Points: 
  • In this free webinar, learn how to successfully set up and manage highly customized CAR T-cell therapy clinical trials.
  • Introducing new CAR T-cell therapies to the market requires extensive strategizing and planning for clinical trials as well as post-marketing follow-up.
  • This webinar emphasizes the challenges encountered and the importance of customized solutions in genomics, flow cytometry, biomarkers and clinical trial operations for successful CAR T-cell therapy clinical trials.
  • Register for this webinar today to learn more about customized solutions for successful CAR T-cell therapy clinical trials.

Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024

Retrieved on: 
Wednesday, March 6, 2024
CDMO, Operating cost, Biotechnology, CGT

The company expects results in the third quarter of fiscal 2024 to include:

Key Points: 
  • The company expects results in the third quarter of fiscal 2024 to include:
    Revenues for the third quarter of fiscal 2024 were $33.8 million, representing an 11% decrease as compared to revenues of $38.0 million recorded in the same prior year period and a 33% increase as compared to revenues of $25.4 million recorded in the second quarter of fiscal 2024.
  • For the first nine months of fiscal 2024, revenues were $96.9 million, a decrease of approximately 11% compared to $109.5 million in the same prior year period.
  • On January 31, 2024, Avid reported cash and cash equivalents of $30.7 million, compared to $38.5 million on April 30, 2023.
  • Avid estimates that its combined mammalian and CGT facilities now have a total revenue generating capacity of up to approximately $400mm annually.

Canada’s Got Talent Reveals Showstopping Acts for The Million Dollar Season, Courtesy of Rogers

Retrieved on: 
Tuesday, March 5, 2024
OLG, Citytv, Carbonear, Kardinal Offishall, Dream, Showtime, EYE, Niagara Fallsview Casino Resort, CGT, Columbidae, CIBC

TORONTO, March 05, 2024 (GLOBE NEWSWIRE) -- It’s almost showtime! As we gear up to take centre stage, Citytv reveals the showstopping performers appearing on Canada’s Got Talent’s Million Dollar Season, thanks to Rogers, beginning Tuesday, March 19 at 8 p.m. ET/PT with a two-hour episode on Citytv or stream anytime on Citytv+. The highly anticipated talent competition series spotlights 116 acts on the Canadian stage as they face the #CGT judges – Howie Mandel, Lilly Singh, Trish Stratus, Kardinal Offishall – and compete to win the grand prize.

Key Points: 
  • As we gear up to take centre stage, Citytv reveals the showstopping performers appearing on Canada’s Got Talent’s Million Dollar Season, thanks to Rogers, beginning Tuesday, March 19 at 8 p.m. ET/PT with a two-hour episode on Citytv or stream anytime on Citytv+.
  • The winner of Canada’s Got Talent’s Million Dollar Season receives a life-changing prize of $1M – the biggest cash prize in Canadian television history – thanks to Rogers, plus financial advice from CIBC.
  • Together with Canada’s Got Talent, Rogers is committed to investing in premium original Canadian content while fostering homegrown talent.
  • Contestants for Canada’s Got Talent’s Million Dollar Season, thanks to Rogers, are listed below.